By investigating the association between genetic loci related to Alzheimer's disease and neuroimaging measures related to disease risk, researchers may have uncovered additional evidence that several previously studied genetic variants are associated with the development and progression of Alzheimer's disease and also may have identified new genetic risk factors for further study, according to a report in the June issue of Archives of Neurology, one of the JAMA/Archives journals.
"The mechanisms underlying Alzheimer's disease onset and progression remain largely unexplained," the authors write as background information in the article. Twin studies have suggested that the condition is 60 percent to 80 percent heritable. Until recently, only one genetic variant--known as APOE--was shown to influence Alzheimer's disease risk and age at onset. However, new findings from genome-wide association studies have identified three additional loci (specific locations of genetic variants on chromosomes) that confer risk of Alzheimer's disease.
Neuroimaging measures--including the volume of hippocampus, amygdala and other brain structures--also correlate with the risk and progression of Alzheimer's disease. "The demonstration that recently discovered genetic risk factors for Alzheimer's disease also influence these neuroimaging traits would provide important confirmation of a role for these genetic variants and suggest mechanisms through which they might be acting," the authors write.
Alessandro Biffi, M.D., and Christopher D. Anderson, M.D., of Massachusetts General Hospital, Boston, and Broad Institute, Cambridge, Mass., and colleagues studied the associations between genes and neuroimaging results among 168 individuals with probable Alzheimer's disease, 357 with mild cognitive impairment (a precursor to Alzheimer's disease) and 215 who were cognitively normal.
The four loci previously associated with Alzheimer's disease were assessed, along with six neuroimaging traits linked to Alzheimer's disease. The APOE gene had the strongest association with clinical Alzheimer's disease, and was associated with all the neuroimaging traits except one. The other candidate genes showed a significant cumulative effect on the neuroimaging measures analyzed.
"Our results indicate that APOE and other previously validated loci for Alzheimer's disease affect clinical diagnosis of Alzheimer's disease and neuroimaging measures associated with disease," the authors write. "These findings suggest that sequence variants that modulate Alzheimer's disease risk in recent genome-wide association studies may act through their influence on neuroimaging measures."
In addition, the genetic analysis of neuroimaging traits identified two new target gene locations--BIN1 and CNTN5--of heightened interest for their relationship with Alzheimer's disease. "Although our results for these loci can only be considered preliminary, they may help prioritize targets for future genetic studies and genome-wide association studies in Alzheimer's disease, particularly given their association with neuroimaging correlates of Alzheimer's disease and disease status," the authors write. They add that independent evidence for an association between the BIN1 gene location and Alzheimer's disease emerged in a recent meta-analysis.
(Arch Neurol. 2010;67:677-685. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Findings Herald New Era of Genetic Studies
"While we have understood the bases for mendelian, early-onset Alzheimer's disease for nearly two decades, elucidation of the genetic risks for late-onset disease beyond the apolipoprotein E locus, discovered in 1993, had been painfully slow until last year," write John Hardy, Ph.D., of University College London Institute of Neurology, and Julie Williams, Ph.D., of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff, Wales, in an accompanying editorial.
"With the benefit of hindsight, we now have some indication of why no other risk loci were found during this period; simply, there are no other loci with similar effect sizes to apolipoprotein E to be found. Now, however, with the advent of whole-genome associations, we are beginning to find the weaker risk loci for the disease."
"These findings, and the genome-wide studies that presaged them, mark a new period of optimism for those of us who study the etiologies of complex diseases of the nervous system," Drs. Hardy and Williams write. "While the drought of genetic findings in Alzheimer's disease has lasted a long time, the flood of new findings have been a reward worth waiting for."
(Arch Neurol. 2010;67:663-664. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including author contributions and affiliations, financial disclosures, funding and support, etc.